BioGaia AB Class B (SE:BIOG.B)
:BIOG.B
Top Page
BioGaia AB
(BIOG.B)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr129.00
▲(22.16% Upside)
Action:DowngradedDate:02/18/26
The score is supported primarily by strong financial quality (consistent revenue growth and a very low-risk, near debt-free balance sheet). It is held back by weak technical momentum (negative MACD, below key moving averages) and a relatively high P/E that looks less compelling given recent margin compression and softer free cash flow.
Positive Factors
Conservative balance sheet / near-zero leverage
Near-zero debt and a very conservative balance sheet materially reduce financial risk and preserve strategic optionality. Over 2–6 months this supports funding for clinical studies, geographic expansion or marketing from internal resources, and cushions against cyclical shocks without refinancing pressure.
Negative Factors
Margin compression and falling net income
A multi-year decline in net margin from ~34% to ~22% indicates rising cost pressures or increased spending intensity that outpaced revenue growth. If sustained, this structural margin erosion can reduce free cash flow, weaken returns on invested capital, and constrain long-term capital allocation choices.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / near-zero leverage
Near-zero debt and a very conservative balance sheet materially reduce financial risk and preserve strategic optionality. Over 2–6 months this supports funding for clinical studies, geographic expansion or marketing from internal resources, and cushions against cyclical shocks without refinancing pressure.
Read all positive factors
BioGaia AB (BIOG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr12.00B
Dividend Yield1.95%
Average Volume (3M)124.05K
Price to Earnings (P/E)32.3
Beta (1Y)0.41
Revenue Growth7.88%
EPS Growth-6.35%
CountrySE
Employees224
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.98
Shares Outstanding98,497,170
10 Day Avg. Volume90,103
30 Day Avg. Volume124,054
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.04
Revenue Forecast (FY)kr1.66B
BioGaia AB Business Overview & Revenue Model
Company Description
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, ...
How the Company Makes Money
BioGaia makes money primarily by commercializing its probiotic strains and finished probiotic products. Key revenue streams typically include: (1) Sales of finished products under BioGaia-owned brands: revenue from selling branded probiotic drops,...
BioGaia AB Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.54B | 1.42B | 1.30B | 1.10B | 785.11M |
| Gross Profit | 1.13B | 1.03B | 950.19M | 801.93M | 582.95M |
| EBITDA | 454.33M | 539.44M | 494.92M | 476.89M | 276.86M |
| Net Income | 332.76M | 351.39M | 365.35M | 373.77M | 196.27M |
Balance Sheet | |||||
| Total Assets | 1.60B | 2.03B | 2.33B | 2.21B | 2.13B |
| Cash, Cash Equivalents and Short-Term Investments | 801.31M | 1.22B | 1.54B | 1.49B | 1.48B |
| Total Debt | 0.00 | 7.10M | 8.80M | 20.09M | 10.40M |
| Total Liabilities | 283.59M | 310.07M | 302.85M | 241.55M | 250.69M |
| Stockholders Equity | 1.31B | 1.72B | 2.03B | 1.97B | 1.88B |
Cash Flow | |||||
| Free Cash Flow | 302.97M | 359.06M | 377.25M | 301.03M | 215.50M |
| Operating Cash Flow | 306.57M | 373.22M | 425.96M | 318.94M | 221.88M |
| Investing Cash Flow | -3.34M | -14.07M | -50.94M | -18.14M | -126.97M |
| Financing Cash Flow | -709.87M | -689.72M | -308.42M | -313.59M | -81.85M |
BioGaia AB Technical Analysis
Positive
105.60
Price Trends
110.86
Positive
107.32
Positive
104.98
Positive
Market Momentum
2.43
Negative
60.58
Neutral
66.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOG.B, the sentiment is Positive. The current price of 105.6 is below the 20-day moving average (MA) of 115.00, below the 50-day MA of 110.86, and above the 200-day MA of 104.98, indicating a bullish trend. The MACD of 2.43 indicates Negative momentum. The RSI at 60.58 is Neutral, neither overbought nor oversold. The STOCH value of 66.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOG.B.
BioGaia AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | kr12.00B | 32.29 | 24.35% | 1.95% | 7.88% | -6.35% | |
56 Neutral | kr629.54M | -60.92 | -48.65% | ― | -60.33% | 58.04% | |
56 Neutral | kr752.48M | -8.89 | ― | ― | 19.17% | 24.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | kr4.21B | 93.57 | 0.88% | 0.66% | 6.65% | 1.41% | |
47 Neutral | kr722.88M | -8.03 | ― | ― | -8.79% | -91.09% | |
44 Neutral | kr171.22M | -4.22 | -90.66% | ― | ― | 15.74% |
* General Sector Average
SE:BIOG.B
BioGaia AB
118.60
29.60
33.26%
SE:ORX
Orexo AB
20.70
7.72
59.48%
SE:ALZCUR
AlzeCure Pharma AB
1.49
-0.88
-37.00%
SE:SECARE
Swedencare AB
26.35
-7.70
-22.61%
SE:NANEXA
Nanexa AB
3.83
2.76
258.15%
SE:ENZY
Enzymatica AB
3.10
-0.27
-8.01%
BioGaia AB Corporate Events
BioGaia Sets May 7 AGM to Vote on Board Slate and New Performance Share Plan
Mar 30, 2026
BioGaia AB has convened its Annual General Meeting for 7 May 2026 in central Stockholm, setting out participation rules for shareholders, including registration deadlines and procedures for nominee-registered holdings and proxy representation. The...
BioGaia Publishes 2025 Annual and Sustainability Report
Mar 30, 2026
BioGaia AB has released its 2025 Annual and Sustainability Report, outlining its financial metrics, strategic framework, and global product portfolio alongside an overview of direct markets. The report also details the company’s sustainabili...
BioGaia study links infant probiotic use to sharply lower childhood abdominal pain
Mar 20, 2026
BioGaia has reported results from a 10-year follow-up study showing that early-life supplementation with its probiotic strain Limosilactobacillus reuteri Protectis is associated with a substantially lower prevalence of functional abdominal pain in...
BioGaia Takes Full Control of U.S. Distributor Nutraceutics
Mar 17, 2026
BioGaia has moved to take full control of its U.S. distribution by exercising an option to buy the remaining 20 percent of Nutraceutics, parent of BioGaia USA, its exclusive distributor in the American market. The deal, effective April 1, 2026 for...
BioGaia Deepens European Push With Expanded Ewopharma Distribution Deal
Feb 26, 2026
BioGaia AB has renewed and expanded its long-standing distribution agreement with Ewopharma, a pharmaceutical marketing and commercialization partner active in Central Eastern Europe and Switzerland. Under the new deal, Ewopharma will distribute a...
BioGaia’s Q4 Surge Offsets Margin Pressure as 2025 Profit Dips and Dividend Is Cut
Feb 12, 2026
BioGaia reported a strong fourth quarter of 2025, with net sales rising 21% to SEK 440.6 million and organic growth of 32%, driven by robust gains in both Pediatrics and Adult Health. Operating profit increased 17% to SEK 121 million, profit after...
BioGaia Flags Strong Fourth-Quarter Sales and Profit Beat
Feb 3, 2026
BioGaia said its preliminary results for the fourth quarter of 2025 will exceed market expectations, with sales estimated at SEK 441 million, up 21% year-on-year (32% excluding currency effects), partly boosted by around SEK 35 million in quarterl...
BioGaia Sets February 12 Date for Q4 2025 Results and Analyst Audiocast
Feb 2, 2026
BioGaia will publish its financial report for the fourth quarter of 2025 on 12 February 2026 at around 8:00 a.m. CET, followed by a live audiocast at 9:30 a.m. CET where CEO Theresa Agnew and CFO Alexander Kotsinas will present the results and tak...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.